Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2014, Article ID 594930, 8 pages
http://dx.doi.org/10.1155/2014/594930
Review Article

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials

1Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510515, China
2Department of Internal Medicine, Nanfang Hospital of Southern Medical University, Luohu District, Guangdong 510515, China

Received 14 February 2014; Revised 29 April 2014; Accepted 29 April 2014; Published 25 May 2014

Academic Editor: Antoni Castells

Copyright © 2014 Yan-xian Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://globocan.iarc.fr/Default.aspx.
  2. D. J. Hicklin and L. M. Ellis, “Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 1011–1027, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Tournigand, T. André, E. Achille et al., “FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study,” Journal of Clinical Oncology, vol. 22, no. 2, pp. 229–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Colucci, V. Gebbia, G. Paoletti et al., “Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 4866–4875, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Cassidy, S. Clarke, E. Díaz-Rubio et al., “Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2006–2012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Cassidy, J. Tabernero, C. Twelves et al., “XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2084–2091, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Porschen, H.-T. Arkenau, S. Kubicka et al., “Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group,” Journal of Clinical Oncology, vol. 25, no. 27, pp. 4217–4223, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. M. Goldberg, D. J. Sargent, R. F. Morton et al., “A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 23–30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. L. T. Macedo, A. B. C. Lima, and A. D. Sasse, “Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups,” BMC Cancer, vol. 12, article 89, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Passardi, E. Scarpi, L. Cavanna et al., “Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): final results from the Itaca randomized clinical trial,” Journal of Clinical Oncology, vol. 31, supplement 15, p. 3517, 2013. View at Google Scholar
  12. F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher et al., “Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 60–65, 2003. View at Google Scholar · View at Scopus
  13. F. F. Kabbinavar, J. Schulz, M. McCleod et al., “Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3697–3705, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. B. Saltz, S. Clarke, E. Díaz-Rubio et al., “Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2013–2019, 2008. View at Google Scholar
  15. G. P. Stathopoulos, C. Batziou, D. Trafalis et al., “Treatment of colorectal cancer with and without bevacizumab: a phase III study,” Oncology, vol. 78, no. 5-6, pp. 376–381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. N. C. Tebbutt, K. Wilson, V. J. Gebski et al., “Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX Study,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3191–3198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 11–12, 1996. View at Google Scholar
  18. J. A. C. Sterne, M. Egger, and G. D. Smith, “Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis,” British Medical Journal, vol. 323, no. 7304, pp. 101–105, 2001. View at Google Scholar · View at Scopus
  19. Cochrane IMS, http://tech.cochrane.org/revman/download.
  20. J. Bennouna, J. Sastre, D. Arnold et al., “Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial,” Lancet Oncology, vol. 14, no. 1, pp. 29–37, 2013. View at Google Scholar
  21. M. K. Boisen, J. S. Johansen, C. Dehlendorff et al., “Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer,” Annals of Oncology, vol. 24, no. 10, pp. 2554–2559, 2013. View at Google Scholar
  22. F. Petrelli, A. Coinu, M. Cabiddu et al., “KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials,” Medical Oncology, vol. 30, no. 3, p. 650, 2013. View at Google Scholar
  23. K. Pogue-Geile, G. Yothers, Y. Taniyama et al., “Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08,” Journal of the National Cancer Institute, vol. 105, no. 13, pp. 989–992, 2013. View at Google Scholar
  24. E. Bria, R. J. Gralla, H. Raftopoulos, and D. Giannarelli, “Comparing two methods of meta-analysis in clinical research—individual patient data-based (IPD) and literature-based abstracted data (AD) methods: analyzing five oncology issues involving more than 10, 000 patients in randomized clinical trials (RCTs),” Journal of Clinical Oncology, vol. 25, no. 18, supplement, abstract 6512, 2007. View at Google Scholar